Navigation Links
Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
Date:1/17/2008

KENILWORTH, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) announced that Nippon Organon K.K., now part of Schering-Plough, has filed a New Drug Application with the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking marketing approval for its novel selective relaxant binding agent (SRBA), sugammadex.

Sugammadex is specifically designed to rapidly reverse to rapidly reverse the effects of certain muscle relaxants, rocuronium bromide (marketed in the U.S. as ZEMURON(R) and in Japan as ESLAX(R)), as well as vecuronium bromide (marketed in Japan as MUSCULAX(R)). Muscle relaxants are used as part of general anesthesia during surgical procedures.

The company announced on January 2, 2008, that the U.S. Food and Drug Administration (FDA) has assigned priority review status to the New Drug Application (NDA) filing for sugammadex. Additionally, the Marketing Authorization Application for sugammadex was accepted for review by the European Medicines Agency (EMEA) in July 2007.

Schering-Plough acquired sugammadex through its combination with Organon BioSciences on November 19, 2007.

About Sugammadex

Sugammadex is a novel selective relaxant binding agent (SRBA) under development by Organon, a part of Schering-Plough Corporation. Sugammadex was designed to reverse the effects of rocuronium bromide or vecuronium bromide, muscle relaxants commonly used during surgeries that require profound muscle relaxation. Anesthesiologists use muscle relaxation to improve surgical conditions, to facilitate intubation and mechanical ventilation, and to reduce the chance of complications.

In clinical trials to date, sugammadex has demonstrated the ability to rapidly reverse shallow an
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... METTLER TOLEDO recently announced t...inar, “The Role of Process Analytical Techno...g” on December 1, 2009. , ...e Role of Process Analytical Technology (PAT) in G...ecember 1, Process Analytical Technology (PAT) cas...
(Date:11/19/2009)..., ,, BETHESDA, Md., Nov. 19 /PRNewswire-Fir...an innovator in biotechnology for diabetes therapy...lting services to food, supplement, biotechnology ...losed the previously reported $6.3 million registe... 2,760,870 shares of its common stock and warrants...
(Date:11/19/2009)...MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeuti...tient in a randomized Phase 2B study of AEG35156, ...lopment for multiple oncology indications. ,, T... 2 Study of the X-Linked Inhibitor of Apoptosis (X...High-dose Cytarabine and Idarubicin in AML Followi...
(Date:11/18/2009)...AVIS, Calif., Nov. 18 Marrone Bio ...lopment and commercialization of effective and env... announced that it has been named an IC20 company ...t and largest national angel investing group. ,... leading to rewarding results for all stakeholders...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Marrone Bio Innovations Named an IC20 Company 2
...12 Ardea Biosciences,Inc. (Nasdaq: RDEA ) today ...nd CEO of Ardea Biosciences, will present at the R...onference., Date: Tuesday, February 19, 2008 ...Carlton Laguna Niguel, Dana Point, CA Webcast: ...tp://www.ardeabio.com About Ardea Biosciences, I...
... and Two Clinical Candidates Featured -, SOUTH SA...s, inc., a privately held company focused on the d...erapeutics (MAbs) for cancer,announced four abstra...ting,of American Association for Cancer Research b... are pleased to have this opportunity to present i...
...12 Mersana, a cancer,therapeutics company, announ...ned the company as Chief Scientific Officer., "We...a team," said,Julie A. Olson, President and CEO at...search and his experience with polymer-based drug ...n to the important impact he will have,on our newe...
Other Biology Technology:Ardea Biosciences to Present at Roth Capital Partners' 20th Annual OC Growth Stock Conference 2Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations 2Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations 3Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D. 2
(Date:11/22/2009)...inventoried an astonishing abundance, diversity an... known sunlight - creatures that somehow manage a ...s (~3 miles) below the ocean waves. , Revealed ...echnologies, animals known to thrive in an eternal...ection of species ranging from crabs to shrimp to ...
(Date:11/22/2009)... a partnership of the University of British Columb...h Research Institute, have uncovered new informati...llowing a stroke, as well as a possible way to mit...ecently published online in Nature Medicine . , ...die even after blood flow has been restored. Resea...
(Date:11/20/2009)...s about the health benefits of having a life partn... where amino acids known as cysteines are much mor...d up with other cysteines. , Now, researchers at... in Belgium, have discovered a new antioxidant sys...ppears in the Nov. 20 issue of the journal Scienc...
Breaking Biology News(10 mins):Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 3Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 4Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 5Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 6Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 7Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 8Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 9New understanding about mechanism for cell death after stroke leads to possible therapy 2Saving the single cysteine: New antioxidant system found 2Study finds rapid growth in health costs hurts economic performance of US industries 52569 1Study finds rapid growth in health costs hurts economic performance of US industries 52569 2Study finds rapid growth in health costs hurts economic performance of US industries 52569 3Noise pollution negatively affects woodland bird communities says CU Boulder study 9334 1Noise pollution negatively affects woodland bird communities says CU Boulder study 9334 2Noise pollution negatively affects woodland bird communities says CU Boulder study 9334 3Newly discovered gene fusion may lead to improved prostate cancer diagnosis 9331 1Newly discovered gene fusion may lead to improved prostate cancer diagnosis 9331 2Newly discovered gene fusion may lead to improved prostate cancer diagnosis 9331 3
...e will carry a price tag of billions of dollars fo...ports from the University of Maryland,s Center for...searchers conclude that the costs have already beg...g existing data with new analysis, the eight studi...e change on Colorado, Georgia, Kansas, Illinois, M...
...urham University (UK) are working on new ways of s...fight against global warming. , The University ha...h will be led by the newly-created position of Pro...rgy. , Researchers aim to find efficient and reli...d power plants and storing it in former oil and ga...
...entists from The Netherlands published online in ...ifies a compound in human saliva that greatly spee...people suffering from chronic wounds related to di...njuries and burns. In addition, because the compou...to become as common as antibiotic creams and rubbi...
Other Biology News:Costs of climate change, state-by-state: Billions, says UMD 2Costs of climate change, state-by-state: Billions, says UMD 3Costs of climate change, state-by-state: Billions, says UMD 4Durham scientists to tackle CO2 storage in global warming challenge 2Licking your wounds: Scientists isolate compound in human saliva that speeds wound healing 2
Mouse Anti-Human BTG2 Polyclonal Antibody, Unconjugated from Novus Biologicals
Attofluor cell chamber from Molecular Probes (Invitrogen)
...ate double-stranded DNA (dsDNA) in solution, even ...DNA is stained with Hoechst 33258 dye, which can b... The kit quantitates dsDNA in the range of 10 ng p...33258, calf thymus DNA standard, and assay buffer ...
Pokeweed Mitogen Spleen Cell Conditioned Medium, 25 mL from StemCell Technologies, Inc.
Biology Products: